10-Q
Quarterly Report
ACTINIUM PHARMACEUTICALS, INC.
ATNM
NYSEAMER
CIK: 1388320
File #: 001-36374
Balance Sheet
28 line items · 2 periods
XBRL
| Item | Mar 31, 2026 | Dec 31, 2025 |
|---|---|---|
Current Assets: | ||
Cash and cash equivalents | 42,132,000 | 47,998,000 |
Prepaid expenses and other current assets | 1,129,000 | 1,383,000 |
Total Current Assets | 43,261,000 | 49,381,000 |
Property and equipment, net of accumulated depreciation of $1,094 and $1,064 | 268,000 | 295,000 |
Restricted cash – long term | 337,000 | 335,000 |
Operating leases right-of-use assets, net | 1,565,000 | 1,754,000 |
Finance leases right-of-use assets, net | 7,000 | 10,000 |
Total Assets | 45,438,000 | 51,775,000 |
Current Liabilities: | ||
Accounts payable and accrued expenses | 6,615,000 | 7,247,000 |
Operating leases current liability | 726,000 | 711,000 |
Finance leases current liability | 8,000 | 11,000 |
Total Current Liabilities | 7,349,000 | 7,969,000 |
Long-term license revenue deferred | 35,000,000 | 35,000,000 |
Long-term operating lease obligations | 785,000 | 972,000 |
Total Liabilities | 43,134,000 | 43,941,000 |
Stockholders’ Equity: | ||
Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,374,991 and 31,195,891 shares issued and outstanding, at March 31, 2026 and December 31, 2025, respectively | 31,000 | 31,000 |
Additional paid-in capital | 417,547,000 | 417,536,000 |
Accumulated other comprehensive loss | (39,000) | (20,000) |
Accumulated deficit | (415,235,000) | (409,713,000) |
Total Stockholders’ Equity | 2,304,000 | 7,834,000 |
Common Stock | 31,000 | 31,000 |
Additional Paid-In Capital | 417,547,000 | 417,536,000 |
Accumulated Other Comprehensive Loss | (39,000) | (20,000) |
Accumulated Deficit | (415,235,000) | (409,713,000) |
Total Liabilities and Stockholders’ Equity | 45,438,000 | 51,775,000 |